Effect of Reduced-Dose Capecitabine Plus Cetuximab as Maintenance Therapy for RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Clinical Trial.

ABSTRACT:

Importance

Fluorouracil-based chemotherapy combined with anti-epidermal growth factor receptor/vascular endothelial growth factor therapy is the standard first-line treatment for metastatic colorectal cancer followed by low-intensity maintenance therapy to balance the clinical efficacy and adverse effects (AEs). However, there have been concerns about the AEs of capecitabine plus cetuximab as a maintenance therapy in patients with RAS wild-type metastatic colorectal cancer.

Objective

To evaluate the biological activity and safety of capecitabine plus cetuximab as a novel maintenance therapy for RAS wild-type metastatic colorectal cancer.

Design, setting, and participants

This phase 2 prospective clinical trial was conducted from April 29, 2016, to April 29, 2019, at 5

SUBMITTER: Wang L 

PROVIDER: S-EPMC7372324 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature